Patterns of Performance of Retroperitoneal Lymph Node Dissections by American Urologists: Most Retroperitoneal Lymph Node Dissections in the United States Are Performed by Low-volume Surgeons

被引:22
作者
Flum, Andrew S.
Bachrach, Laurie
Jovanovic, Borko D.
Helenowski, Irene B.
Flury, Sarah C.
Meeks, Joshua J. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA
关键词
TESTICULAR CANCER; CHEMOTHERAPY; SURVIVAL; IMPACT; TRIAL;
D O I
10.1016/j.urology.2014.07.054
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To characterize the current patterns of retroperitoneal lymph node dissection (RPLND) performance among practicing US urologists. METHODS Six-month case log data of urologists certifying between 2003 and 2013 were obtained from the American Board of Urology. Cases specifying both an International Classification of Diseases, Ninth Revision code for testis cancer and a Current Procedural Terminology code for RPLND were analyzed for surgeon-specific variables. RESULTS Among 8545 certifying urologists, 290 (3.4% of all) urologists logged 553 RPLNDs in the case log system with 21 (3.6%) performed laparoscopically. Median number of RPLNDs logged annually was 1 (range, 1-59; interquartile range, 1-1) with 3 urologists performing 23% of all RPLNDs. Seventy-five percent of urologists logged a single RPLND. Urologists who logged 2 RPLNDs in a year were in the top 25% of performers with over half (52%) of all RPLNDs performed by urologists who logged 1 or 2 RPLND. On univariate regression analysis, oncology specialization (odds ratio, 5.1 [95% confidence interval, 2.2-11.6; P = .0001]) and noneprivate practice type (odds ratio, 2.8 [95% confidence interval, 1.1-7.1; P = .03]) were predictive of top 10% (>= 3 cases) surgeon RPLND volume. CONCLUSION Despite the critical importance of the surgical quality for outcomes of patients with testis cancer, the majority of surgeons performing RPLND are certifying for the first time and log only 1 RPLND. (C) 2014 Elsevier Inc.
引用
收藏
页码:1325 / 1328
页数:4
相关论文
共 14 条
[1]   PROGNOSTIC FACTORS IN UNSELECTED PATIENTS WITH NONSEMINOMATOUS METASTATIC TESTICULAR CANCER - A MULTICENTER EXPERIENCE [J].
AASS, N ;
KLEPP, O ;
CAVALLINSTAHL, E ;
DAHL, O ;
WICKLUND, H ;
UNSGAARD, B ;
BALDETORP, L ;
AHLSTROM, S ;
FOSSA, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (05) :818-826
[2]   Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German testicular cancer study group [J].
Albers, Peter ;
Siener, Roswitha ;
Krege, Susanne ;
Schmelz, Hans-Uwe ;
Dieckmann, Klaus-Peter ;
Heidenreich, Axel ;
Kwasny, Peter ;
Pechoel, Maik ;
Lehmann, Jan ;
Kliesch, Sabine ;
Koehrmann, Kai-Uwe ;
Fimmers, Rolf ;
Weissbach, Lothar ;
Loy, Volker ;
Wittekind, Christian ;
Hartmann, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :2966-2972
[3]   EAU Guidelines on Testicular Cancer: 2011 Update [J].
Albers, Peter ;
Albrecht, Walter ;
Algaba, Ferran ;
Bokemeyer, Carsten ;
Cohn-Cedermark, Gabriella ;
Fizazi, Karim ;
Horwich, Alan ;
Laguna, Maria Pilar .
EUROPEAN UROLOGY, 2011, 60 (02) :304-319
[4]   Surgeon volume and operative mortality in the United States [J].
Birkmeyer, JD ;
Stukel, TA ;
Siewers, AE ;
Goodney, PP ;
Wennberg, DE ;
Lucas, FL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2117-2127
[5]   The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer [J].
Carver, Brett S. ;
Cronin, Angel M. ;
Eggener, Scott ;
Savage, Caroline J. ;
Motzer, Robert J. ;
Bajorin, Dean ;
Bosl, George J. ;
Sheinfeld, Joel .
UROLOGY, 2010, 75 (06) :1431-1435
[6]   Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma [J].
Collette, L ;
Sylvester, RJ ;
Stenning, SP ;
Fossa, SD ;
Mead, GM ;
de Wit, R ;
de Mulder, PHM ;
Neymark, N ;
Lallemand, E ;
Kaye, SB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (10) :839-846
[7]   AFTER A TREATMENT BREAKTHROUGH - A COMPARISON OF TRIAL AND POPULATION-BASED DATA FOR ADVANCED TESTICULAR CANCER [J].
FEUER, EJ ;
FREY, CM ;
BRAWLEY, OW ;
NAYFIELD, SG ;
CUNNINGHAM, JB ;
GELLER, NL ;
BOSL, GJ ;
KRAMER, BS .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :368-377
[8]   Adverse Prognostic Factors for Testicular Cancer-Specific Survival: A Population-Based Study of 27,948 Patients [J].
Fossa, Sophie D. ;
Cvancarova, Milada ;
Chen, Linlin ;
Allan, Annie L. ;
Oldenburg, Jan ;
Peterson, Derick R. ;
Travis, Lois B. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :963-970
[9]   MANAGEMENT OF MALIGNANT TERATOMA - DOES REFERRAL TO A SPECIALIST UNIT MATTER [J].
HARDING, MJ ;
PAUL, J ;
GILLIS, CR ;
KAYE, SB .
LANCET, 1993, 341 (8851) :999-1002
[10]   The impact of provider volume on outcomes from urological cancer therapy [J].
Joudi, FN ;
Konety, BR .
JOURNAL OF UROLOGY, 2005, 174 (02) :432-438